MERK Merck Tbk


Saham MERK Merck Tbk - Berita, Prospek, dan Analisa - :
Stocks Asia - Berita saham, analisis saham, dan prospek saham
Tip: Gunakan untuk menyimpan saham-saham favorit
MERK U.S. coronavirus case tally tops 12 million amid growing fears that Thanksgiving travel will spark another surge of infections - MarketWatch
24 Nov 2020 00:09 (1 hari 23 jam lalu) - The global case tally of the coronavirus illness COVID-19 rose to 58.7 million on Monday, and the U.S. tally rose above 12 million, with new daily infections heading toward 200,0000 amid growing fears that Thanksgiving travel will spark a further U.S. surge. The pace of spread is accelerating rapidly. It took the U.S. six days to climb to 12 million cases from 11 million, after taking seven days to rise to 11 million from 10 million and 11 days to get to 10 million from 9 million. “Four days before a holiday with potentially the most indoor and in-person gatherings of the year in the U.S., the virus is here and more prevalent than ever,” sa ...
MERK Regeneron, Merck Rise Premarket; Kellogg Drops By Investing.com
23 Nov 2020 15:31 (2 hari 8 jam lalu) - By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Monday, November 23rd. Please refresh for updates. - Regeneron (NASDAQ: REGN) stock rose 3.9% after the biotech’s experimental drug to treat Covid-19 patients, already used by President Trump, was granted emergency use authorization by the Food nd Drug Administration. - AstraZeneca (NASDAQ: AZN) ADR fell 1% despite its vaccine news. The pharma giant said there were two different dosing regimes, one produced 90% effectiveness and the other 62%. News of the later has dragged the share price down, as it is considerably below the 95% level seen in the Pfizer (NYSE: PFE) and M ...
MERK Beban Turun, Laba MERK Melonjak 223 Persen Pada Akhir September 2020
19 Nov 2020 16:24 (6 hari lalu) - Pasardana.id- PT Merck Tbk (MERK) pada akhir September tahun 2020 mencatatkan laba sebesar Rp55,067 miliar, atau melonjak 223,52 persen dibanding akhir kuartal III 2019, yang mencatatkan laba sebesar Rp17,068 miliar. Data tersebut tersaji dalam laporan keuangan kuartal III 2020 emiten farmasi yang dimuat pada laman Bursa Efek Indonesia, Kamis (19/11/2020). Padahal, dalam laporan keuangan tersebut tertera pendapatan pada akhir kuartal III tahun 2020 tercatat sebesar Rp439,82 miliar, atau turun 11,67 persen dibanding periode yang sama tahun 2019, yang tercatat sebesar Rp497,97 miliar. Tapi beban pokok penjualan usaha tercatat sebesar Rp240,2 ...
Artikel lain:
    icon EmitenNews.com:   Beban Turun, Laba Merck (MERK) Melonjak 223 Persen di Kuartal III 2020 - Emitennews - 20 Nov 2020 12:04 (5 hari lalu)
MERK Laba Bersih Merck Melonjak Tajam 223,52% | Neraca.co.id
20 Nov 2020 11:25 (5 hari lalu) - NERACA Jakarta – Emiten farmasi, PT Merck Tbk (MERK) berhasil membukukan kinerja keuangan yang apik di kuartal tiga 2020. Dimana perseroan mencatatkan laba sebesar Rp55,067 miliar atau melonjak 223,52% dibanding akhir kuartal III 2019 yang mencatatkan laba sebesar Rp17,068 miliar. Informasi tersebut disampaikan perseroan dalam siaran persnya di Jakarta, kemarin. Sebaliknya, pendapatan pada akhir kuartal III tahun 2020 tercatat sebesar Rp439,82 miliar atau turun 11,67% dibanding periode yang sama tahun 2019 yang tercatat sebesar Rp497,97 miliar. Tapi beban pokok penjualan usaha tercatat sebesar Rp240,24 miliar atau turun 25,69% dibanding akh ...
MERK Penyampaian Laporan Keuangan Interim Yang Tidak Diaudit
MERK Berkshire's bet a bright spot in gloomy year for Big Pharma stocks By Reuters
18 Nov 2020 14:16 (7 hari lalu) - By Lewis Krauskopf NEW YORK (Reuters) - Berkshire Hathaway Inc 's (N: BRKa) new bet on the U.S. pharmaceutical industry signals hope for shares of large drug companies, which have lagged a broad market rally amid concern about efforts to rein in prescription drug prices. Drug stocks largely outperformed on Tuesday, a day after Warren Buffett's conglomerate, long underweight in the healthcare sector, revealed $5.7 billion of new investments in Abbvie Inc (N: ABBV), Bristol-Myers Squibb Co (N: BMY), Merck & Co (N: MRK) and Pfizer Inc (N: PFE), whose vaccine has demonstrated effectiveness in late-stage studies against COVID-19. “It’s a recogn ...
MERK Warren Buffett’s Berkshire Hathaway Confirms Apple Stock Sale, Buys of Pfizer, Merck - MarketWatch
17 Nov 2020 05:57 (8 hari lalu) - Warren Buffett’s Berkshire Hathaway has confirmed that it trimmed holdings in Apple stock in the third quarter. The conglomerate also initiated positions in drug giants AbbVie, Pfizer, and Merck, and slashed its stake in JPMorgan Chase. Berkshire Hathaway (ticker: BRK.B) disclosed the trades, among others, in a form it filed on Monday with the Securities and Exchange Commission. The company didn’t respond to a request for comment. Barron’s reported earlier this month that Berkshire Hathaway had sold about 38 million shares of Apple (AAPL). The latest filing shows that Berkshire Hathaway sold 36.3 million shares in the quarter, in line with ...
MERK Laporan Bulanan Registrasi Pemegang Efek
MERK Merck to buy VelosBio for $2.75 billion to bolster oncology pipeline - MarketWatch
05 Nov 2020 18:40 (20 hari lalu) - Shares of Merck & Co. Inc. MRK, +4.81% rose 1.0% in premarket trading Thursday, after the drug maker announced a deal to buy privately held biopharmaceutical company VelosBio Inc. for $2.75 billion in cash. The deal is expected to close by the end of 2020. In October, VelosBio had initiated a Phase 2 trial of VLS-101 for the treatment of patients with solid tumors. "At Merck, we continue to bolster our growing oncology pipeline with strategic acquisitions that both complement our current portfolio and strengthen our long-term growth potential," said Dr. Roger Perlmutter, president, Merck Research Laboratories. "Pioneering work by VelosBio ...
Mode seleksi ketat (strict search) ON. Klik di sini untuk melihat lebih banyak artikel.
  Artikel 1 sampai 10